Hospital
Lafourche Parish Hospital Service District No. 1
Lafourche Parish Hospital Service District No. 1 was paid $4.36M by Medicaid between Jan 2018 and Dec 2024, across 60 billing codes. Its largest line is 99283, emergency room visit (moderate) — 48% of everything it billed.
33Billing provider infoLAFOURCHE PARISH HOSPITAL SERVICE DISTRICT NO. 1
CUT OFF, LA 70345
CUT OFF, LA 70345
33aNPI1407883341assigned 06/27/2006
33bProvider typeCritical Access Hospital
28Total paid$4.36M
24GClaims102,843
24DCodes billed60
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#16 of 40
Median peer was paid$3.19M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,217 | $349K | |
| 2019 | 14,234 | $361K | |
| 2020 | 12,128 | $406K | |
| 2021 | 16,548 | $649K | |
| 2022 | 14,769 | $663K | |
| 2023 | 20,389 | $1.16M | |
| 2024incomplete | 10,558 | $764K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 48% | 13,993 | 10,541 | $2.08M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 4,438 | 3,706 | $565K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 1,615 | 1,248 | $378K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 968 | 596 | $342K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 7.0% | 4,285 | 3,701 | $304K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.0% | 3,961 | 3,260 | $130K |
| 80053 | Comprehensive metabolic panel | 2.5% | 13,834 | 10,862 | $110K |
| 85027 | 1.6% | 14,174 | 10,820 | $68K | |
| 86710 | 1.2% | 3,065 | 2,467 | $53K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,553 | 2,910 | $48K |
| 36415 | Collection of venous blood by venipuncture | <1% | 16,852 | 12,970 | $37K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 292 | 95 | $25K |
48 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,574 | $23K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 521 | $22K |
| 80061 | Lipid panel | <1% | 2,065 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 598 | $19K |
| 87430 | <1% | 1,572 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 681 | $18K |
| 93000 | <1% | 279 | $16K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 253 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 482 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,204 | $10K |
| 81001 | <1% | 3,607 | $6K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,120 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 39 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 477 | $3K |
| 0001A | <1% | 119 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 65 | $2K |
| 81015 | <1% | 734 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 429 | $2K |
| 83735 | <1% | 473 | $2K | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 88 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 77 | $1K |
| 85730 | <1% | 272 | $908.67 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 31 | $851.66 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 140 | $780.06 |
| 84703 | <1% | 92 | $705.94 | |
| 84484 | <1% | 143 | $648.44 | |
| 85610 | <1% | 269 | $631.21 | |
| J3490 | Unclassified drugs | <1% | 104 | $513.80 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 13 | $476.56 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 13 | $476.56 |
| 83690 | <1% | 109 | $467.29 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 32 | $424.32 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 63 | $379.68 |
| 87807 | <1% | 39 | $353.70 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 432 | $338.63 |
| 82150 | <1% | 90 | $317.52 | |
| 85379 | <1% | 37 | $193.42 | |
| 86803 | <1% | 19 | $171.24 | |
| 86140 | <1% | 63 | $168.56 | |
| 85651 | <1% | 49 | $162.26 | |
| 83525 | <1% | 12 | $137.16 | |
| 80076 | <1% | 13 | $73.53 | |
| 81003 | <1% | 27 | $42.23 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 70 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 93 | $0.00 |
| 91300 | 0% | 70 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 44 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLLINS, KAREN (CHIEF EXECTIVE OFFICIER)
| Provider | Location | Paid |
|---|---|---|
| Safe Residential Care, LLC | Westbrook, ME | $94.64M |
| Lafourche Parish Hospital Service District No. 1 | Cut Off, LA | $974K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.